Summarized by Masters of Longevity from Longevity Technology.
A biotech leadership update and company transition story that previews why an oral tau-targeting drug is moving from lab to early human testing.
Key Takeaways
- Cara Cassino was appointed Interim President and CEO thirteen months after joining the board.
- Oligomerix’s oral tau inhibitor OLX-07010 cleared a Phase 1a safety trial in healthy volunteers.
- Preclinical studies showed OLX-07010 blocked tau accumulation across multiple animal models.
